Document is current
Any future updates will be listed below
-
Authors
Phongpreecha, Thanaphong http://orcid.org/0000-0001-9245-6686
Cholerton, Brenna http://orcid.org/0000-0002-2139-987X
Mata, Ignacio F. http://orcid.org/0000-0003-1198-0633
Zabetian, Cyrus P. http://orcid.org/0000-0002-7739-4306
Poston, Kathleen L. http://orcid.org/0000-0003-3424-7143
Aghaeepour, Nima
Tian, Lu
Quinn, Joseph F.
Chung, Kathryn A.
Hiller, Amie L.
Hu, Shu-Ching
Edwards, Karen L.
Montine, Thomas J.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684, P50 NS062684)
U.S. Department of Veterans Affairs (101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702, 101 CX001702)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- License Information
-
More Information
Article History
Received: 20 February 2020
Accepted: 22 July 2020
First Online: 25 August 2020
Competing interests
: The authors declare no competing interests related to the current manuscript. Full financial disclosure is provided below: T.P. is supported by grants from the NIH and the Scully Initiative Fund. B.C. is supported by grants from the NIH. I.F.M. is funded by grants from the Parkinson’s Foundation, American Parkinson’s Disease Association, and the National Institutes of Health. C.P.Z. is supported by grants from the American Parkinson Disease Association. Department of Veteran Affairs, and NIH, and a gift from the Dolsen Foundation. K.L.P. reports honoraria from invited scientific presentations to universities and professional societies not exceeding $5000/yr, is reimbursed by Sanofi, AstraZeneca, and Sangamo BioSciences for the conduct of clinical trials, has received consulting fees from Allergan and Curasen, and is funded by grants from the Michael J Fox Foundation for Parkinson’s Research and the NIH. N.A. is supported by grants from the NIH, the American Heart Association, the Doris Duke Charitable Foundation, the Bill and Melinda Gates Foundation, the March of Dimes, the Food and Drug Administration, the Burroughs Wellcome Fund, L.T. is supported by grants from the NIH. J.F.Q. is reimbursed by Prothena and Roche for the conduct of clinical trials and by vTv Pharmaceuticals for DSMB service. J.F.Q. is also supported by grants from the NIH and Department of Veterans Affairs. K,A.C. is funded by a VA Merit Grant. A.L.H. is reimbursed by Theravance Inc. for conducting clinical trials and supported by grants from NIH and the Huntington’s Disease Society of America. S-.C.H. is funded by grants from the NIH and Michael J. Fox Foundation. K.L.E. is funded by grants from the NIH. T.J.M. reports honoraria from invited scientific presentations to universities and professional societies not exceeding $5000 per year and is funded by grants from the NIH, the Michael J. Fox Foundation, the Farmer Family Foundation, and the Scully Initiative Fund.
